直肠周围水凝胶隔离剂置入后前列腺癌剂量递增至82Gy放疗:II期试验3年结果
这项单臂、开放标签、前瞻性研究纳入70例局限性前列腺癌患者,在水凝胶隔离剂置入后行调强放疗剂量递增至82Gy(2Gy/次),64例(91.4%)实际接受82Gy方案。中位随访37.4个月,放疗相关3级胃肠和泌尿不良事件发生率分别为0%和2.9%,水凝胶隔离剂置入相关3级不良事件2例(2.9%),未观察到晚期RTOG≥2级胃肠毒性。作者结论认为水凝胶隔离剂辅助下剂量递增至82Gy安全可行,但需更长随访的试验来证实治疗窗的持续扩大。
要点
- 70例局限性前列腺癌患者中64例(91.4%)接受82Gy放疗,中位随访37.4个月。
- 放疗相关3级胃肠和泌尿不良事件发生率分别为0%和2.9%,水凝胶隔离剂置入相关3级不良事件2例(2.9%)。
- 未观察到晚期RTOG≥2级胃肠毒性,随访期内9例(12.9%)符合生化失败标准。
核心结论
- 作者结论认为,在水凝胶隔离剂辅助下剂量递增至82Gy是安全可行的,至治疗后37.5个月毒性极小,与既往剂量递增至80Gy试验的直肠毒性率相比。
- 作者指出,需要更长随访肿瘤学和功能结局的试验来稳健证实治疗窗的持续扩大。
研究设计与样本
- 单臂、开放标签、前瞻性研究,纳入局限性前列腺癌男性患者。
- 患者在水凝胶隔离剂(SpaceOAR™,Boston Scientific,Marlborough,MA)置入后接受调强放疗剂量递增至82Gy(2Gy/次)。
- 当82Gy计划的直肠剂量约束无法满足时,患者接受标准78Gy(2Gy/次)方案。
- 共同主要终点为3级胃肠和泌尿不良事件发生率(CTCAE v4)及患者报告生活质量(EORTC QLQ-C30和PR25模块),随访至治疗后37.5个月。
- 试验在澳大利亚新西兰临床试验注册中心注册(ACTRN12621000056897),2021年1月22日回顾性注册。
主要发现
- 70例患者接受研究治疗,其中64例(91.4%)接受82Gy疗程。
- 治疗后中位随访时间为37.4个月。
- 放疗相关3级胃肠和泌尿不良事件发生率分别为0%和2.9%。
- 水凝胶隔离剂置入相关3级不良事件2例(2.9%)。
- 仅观察到轻微且短暂的生活质量下降;与基线相比,治疗后13.5个月至37.5个月无临床或统计学显著的生活质量下降。
局限性
- 作者指出需要更长随访肿瘤学和功能结局的试验来稳健证实治疗窗的持续扩大。
- 试验为回顾性注册(2021年1月22日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dose-escalation to above 80 Gy during external beam radiotherapy for localised prostate cancer leads to improved oncological outcomes but also substantially increased rectal toxicity. The aim of this study was to demonstrate the safety and efficacy of escalating the dose to 82 Gy following insertion of a peri-rectal hydrogel spacer (HS) prior to radiotherapy. METHODS: This was a single arm, open-label, prospective study of men with localised prostate cancer who were prescribed a course of intensity modulated radiotherapy escalated to 82 Gy in 2 Gy fractions following insertion of the SpaceOAR™ HS (Boston Scientific, Marlborough, MA). Patients were prescribed a standard course of 78 Gy in 2 Gy fractions where rectal dose constraints could not be met for the 82 Gy plan. The co-primary endpoints were the rate of grade 3 gastrointestinal (GI) and genitourinary (GU) adverse events (CTCAE, v4), and patient-reported quality of life (QoL) (EORTC QLQ-C30 and PR25 modules), up to 37.5 months post-treatment. RESULTS: Seventy patients received treatment on the study, with 64 (91.4%) receiving an 82 Gy treatment course. The median follow-up time post-treatment was 37.4 months. The rate of radiotherapy-related grade 3 GI and GU adverse events was 0% and 2.9%, respectively. There were 2 (2.9%) grade 3 adverse events related to insertion of the HS. Only small and transient declines in QoL were observed; there was no clinically or statistically significant decline in QoL beyond 13.5 months and up to 37.5 months post-treatment, compared to baseline. No late RTOG-defined grade ≥ 2 GI toxicity was observed, with no GI toxicity observed in any patient at 37.5 months post-treatment. Nine (12.9%) patients met criteria for biochemical failure within the follow-up period. CONCLUSIONS: Dose-escalation to 82 Gy, facilitated by use of a hydrogel spacer, is safe and feasible, with minimal toxicity up to 37.5 months post-treatment when compared to rates of rectal toxicity in previous dose-escalation trials up to 80 Gy. Trials with longer follow-up of oncological and functional outcomes are required to robustly demonstrate a sustained widening of the therapeutic window. Trial registration Australian New Zealand Clinical Trials Registry, ACTRN12621000056897 , 22/01/2021. Retrospectively registered.
引用
- See AW, Bowden P, Wells G, et al. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial. Radiat Oncol. 2022. PMID: 35879722. doi:10.1186/s13014-022-02103-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。